Polaryx Therapeutics (PLYX) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PMV Pharmaceuticals is the larger company by market cap ($114.8 million vs $99.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | PMVP |
|---|---|---|
| Share price | $2.00 | $1.52 |
| Market cap | $99.69M | $114.78M |
| 1-day change | 0.00% | +2.01% |
| YTD return | — | +19.20% |
| 1-year return | — | +4.93% |
| 5-year return | — | -93.78% |
| EPS (TTM) | $-0.14 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $48.91 | $1.91 |
| 52-week low | $1.85 | $1.02 |
| Distance from 52-week high | -95.91% | -20.42% |
| Analyst consensus | none | none |
| Avg. price target upside | +275.00% | +176.32% |
| Average volume | 76.41K | 669.16K |
| Shares outstanding | 49.85M | 75.51M |
| Employees | 2 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
PLYX vs PMVP FAQ
Which is bigger, Polaryx Therapeutics or PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $114.78M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Polaryx Therapeutics and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.